Key result
Initiation of serotonin norepinephrine reuptake inhibitors had a similar risk of antihypertensive treatment intensification (aHR 1.01; 95% CI 0.94-1.08) and MACE (aHR 0.98) compared to SSRIs.
Why the study?
To compare the risk of antihypertensive treatment intensification and MACE with the initiation of serotonin norepinephrine reuptake inhibitors versus SSRIs in patients with stable hypertension and depression.
Do serotonin norepinephrine reuptake inhibitors increase the risk of antihypertensive treatment intensification or MACE compared to SSRIs in patients with stable hypertension and depression?
Cohort (n=19,160)
Do serotonin norepinephrine reuptake inhibitors increase the risk of antihypertensive treatment intensification or MACE compared to SSRIs in patients with stable hypertension and depression?
Initiation of SNRIs does not appear to increase the risk of antihypertensive treatment intensification or MACE compared to SSRIs in patients with stable hypertension and depression.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Desai et al. (2022) conducted a cohort in stable hypertension and depression (n=19,160). Serotonin norepinephrine reuptake inhibitors vs. Selective serotonin reuptake inhibitors (SSRIs) was evaluated on Antihypertensive treatment intensification (first occurrence of antihypertensive regimen augmentation or dose escalation) (aHR 1.01, 95% CI 0.94-1.08). Initiation of serotonin norepinephrine reuptake inhibitors had a similar risk of antihypertensive treatment intensification (aHR 1.01; 95% CI 0.94-1.08) and MACE (aHR 0.98) compared to SSRIs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: